Do analysts rate ICCM or GCTK?

IceCure Medical presently has a consensus target price of $62.70, indicating a potential upside of 2,155.40%. Given IceCure Medical's stronger consensus rating and higher possible upside, equities research analysts clearly believe IceCure Medical is more favorable than GlucoTrack. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IceCure Medical 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ICCM or GCTK more profitable?

GlucoTrack has a net margin of 0.00% compared to IceCure Medical's net margin of -441.60%. IceCure Medical's return on equity of -211.73% beat GlucoTrack's return on equity. Company Net Margins Return on Equity Return on Assets IceCure Medical -441.60% -211.73% -119.13% GlucoTrack N/A -581.98% -220.10%

Does the media prefer ICCM or GCTK?

In the previous week, GlucoTrack had 3 more articles in the media than IceCure Medical. MarketBeat recorded 4 mentions for GlucoTrack and 1 mentions for IceCure Medical. IceCure Medical's average media sentiment score of 0.00 equaled GlucoTrack'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IceCure Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GlucoTrack 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend NXL or GCTK?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer NXL or GCTK?

In the previous week, GlucoTrack had 3 more articles in the media than Nexalin Technology. MarketBeat recorded 4 mentions for GlucoTrack and 1 mentions for Nexalin Technology. Nexalin Technology's average media sentiment score of 0.54 beat GlucoTrack's score of 0.00 indicating that Nexalin Technology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nexalin Technology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GlucoTrack 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate CODX or GCTK?

Co-Diagnostics currently has a consensus target price of $67.50, suggesting a potential upside of 4,460.81%. Given Co-Diagnostics' stronger consensus rating and higher probable upside, analysts plainly believe Co-Diagnostics is more favorable than GlucoTrack. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Co-Diagnostics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer CODX or GCTK?

In the previous week, GlucoTrack had 1 more articles in the media than Co-Diagnostics. MarketBeat recorded 4 mentions for GlucoTrack and 3 mentions for Co-Diagnostics. Co-Diagnostics' average media sentiment score of 0.29 beat GlucoTrack's score of 0.00 indicating that Co-Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Co-Diagnostics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GlucoTrack 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate GCTK or QNRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation and earnings, GCTK or QNRX?

Quoin Pharmaceuticals is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GlucoTrack N/A N/A -$19.39M -$18.04 N/A Quoin Pharmaceuticals N/A N/A -$15.81M -$29.56 N/A

Is GCTK or QNRX more profitable?

Quoin Pharmaceuticals' return on equity of -489.85% beat GlucoTrack's return on equity. Company Net Margins Return on Equity Return on Assets GlucoTrack N/A -581.98% -220.10% Quoin Pharmaceuticals N/A -489.85% -221.29%

Does the media favor GCTK or QNRX?

In the previous week, GlucoTrack had 3 more articles in the media than Quoin Pharmaceuticals. MarketBeat recorded 4 mentions for GlucoTrack and 1 mentions for Quoin Pharmaceuticals. GlucoTrack's average media sentiment score of 0.00 equaled Quoin Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GlucoTrack 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Quoin Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate GCTK or HSCS?

HeartSciences has a consensus price target of $8.00, suggesting a potential upside of 273.83%. Given HeartSciences' stronger consensus rating and higher possible upside, analysts plainly believe HeartSciences is more favorable than GlucoTrack. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 HeartSciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, GCTK or HSCS?

HeartSciences is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GlucoTrack N/A N/A -$19.39M -$18.04 N/A HeartSciences N/A N/A -$9.14M -$3.94 N/A

Is GCTK or HSCS more profitable?

HeartSciences' return on equity of -358.60% beat GlucoTrack's return on equity. Company Net Margins Return on Equity Return on Assets GlucoTrack N/A -581.98% -220.10% HeartSciences N/A -358.60% -144.82%

Does the media refer more to GCTK or HSCS?

In the previous week, HeartSciences had 9 more articles in the media than GlucoTrack. MarketBeat recorded 13 mentions for HeartSciences and 4 mentions for GlucoTrack. HeartSciences' average media sentiment score of 0.24 beat GlucoTrack's score of 0.00 indicating that HeartSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GlucoTrack 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral HeartSciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

GlucoTrack (GCTK) Competitors

$0.41 -0.06 (-13.02%)

Closing price 08/3/2026 04:00 PM Eastern

Extended Trading

$0.40 -0.02 (-3.83%)

As of 08/3/2026 07:59 PM Eastern

Compare

GCTK vs. ICCM, NXL, CODX, QNRX, and HSCS

Should you buy GlucoTrack stock or one of its competitors? MarketBeat compares GlucoTrack with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with GlucoTrack include IceCure Medical (ICCM), Nexalin Technology (NXL), Co-Diagnostics (CODX), Quoin Pharmaceuticals (QNRX), and HeartSciences (HSCS).

How does GlucoTrack compare to IceCure Medical?

IceCure Medical (NASDAQ:ICCM) and GlucoTrack (NASDAQ:GCTK) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

IceCure Medical presently has a consensus target price of $62.70, indicating a potential upside of 2,155.40%. Given IceCure Medical's stronger consensus rating and higher possible upside, equities research analysts clearly believe IceCure Medical is more favorable than GlucoTrack.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IceCure Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

GlucoTrack has a net margin of 0.00% compared to IceCure Medical's net margin of -441.60%. IceCure Medical's return on equity of -211.73% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IceCure Medical	-441.60%	-211.73%	-119.13%
GlucoTrack	N/A	-581.98%	-220.10%

IceCure Medical has higher revenue and earnings than GlucoTrack. IceCure Medical is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IceCure Medical	$3.38M	2.82	-$15.06M	-$7.21	N/A
GlucoTrack	N/A	N/A	-$19.39M	-$18.04	N/A

In the previous week, GlucoTrack had 3 more articles in the media than IceCure Medical. MarketBeat recorded 4 mentions for GlucoTrack and 1 mentions for IceCure Medical. IceCure Medical's average media sentiment score of 0.00 equaled GlucoTrack'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IceCure Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GlucoTrack	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

IceCure Medical has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market. Comparatively, GlucoTrack has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market.

0.6% of IceCure Medical shares are owned by institutional investors. Comparatively, 10.9% of GlucoTrack shares are owned by institutional investors. 2.4% of IceCure Medical shares are owned by company insiders. Comparatively, 8.4% of GlucoTrack shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

IceCure Medical beats GlucoTrack on 8 of the 14 factors compared between the two stocks.

How does GlucoTrack compare to Nexalin Technology?

Nexalin Technology (NASDAQ:NXL) and GlucoTrack (NASDAQ:GCTK) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nexalin Technology has higher revenue and earnings than GlucoTrack. Nexalin Technology is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$300K	26.77	-$8.22M	-$0.47	N/A
GlucoTrack	N/A	N/A	-$19.39M	-$18.04	N/A

GlucoTrack has a net margin of 0.00% compared to Nexalin Technology's net margin of -3,018.12%. Nexalin Technology's return on equity of -191.88% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-3,018.12%	-191.88%	-166.43%
GlucoTrack	N/A	-581.98%	-220.10%

Nexalin Technology has a beta of 4, suggesting that its stock price is 300% more volatile than the broader market. Comparatively, GlucoTrack has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market.

0.7% of Nexalin Technology shares are owned by institutional investors. Comparatively, 10.9% of GlucoTrack shares are owned by institutional investors. 16.9% of Nexalin Technology shares are owned by insiders. Comparatively, 8.4% of GlucoTrack shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, GlucoTrack had 3 more articles in the media than Nexalin Technology. MarketBeat recorded 4 mentions for GlucoTrack and 1 mentions for Nexalin Technology. Nexalin Technology's average media sentiment score of 0.54 beat GlucoTrack's score of 0.00 indicating that Nexalin Technology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nexalin Technology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GlucoTrack	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Nexalin Technology beats GlucoTrack on 8 of the 12 factors compared between the two stocks.

How does GlucoTrack compare to Co-Diagnostics?

Co-Diagnostics (NASDAQ:CODX) and GlucoTrack (NASDAQ:GCTK) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

15.0% of Co-Diagnostics shares are owned by institutional investors. Comparatively, 10.9% of GlucoTrack shares are owned by institutional investors. 2.3% of Co-Diagnostics shares are owned by company insiders. Comparatively, 8.4% of GlucoTrack shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

GlucoTrack has a net margin of 0.00% compared to Co-Diagnostics' net margin of -6,760.63%. Co-Diagnostics' return on equity of -164.92% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Co-Diagnostics	-6,760.63%	-164.92%	-141.15%
GlucoTrack	N/A	-581.98%	-220.10%

Co-Diagnostics currently has a consensus target price of $67.50, suggesting a potential upside of 4,460.81%. Given Co-Diagnostics' stronger consensus rating and higher probable upside, analysts plainly believe Co-Diagnostics is more favorable than GlucoTrack.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Co-Diagnostics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

GlucoTrack has lower revenue, but higher earnings than Co-Diagnostics. Co-Diagnostics is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Co-Diagnostics	$620K	8.81	-$46.90M	-$15.77	N/A
GlucoTrack	N/A	N/A	-$19.39M	-$18.04	N/A

In the previous week, GlucoTrack had 1 more articles in the media than Co-Diagnostics. MarketBeat recorded 4 mentions for GlucoTrack and 3 mentions for Co-Diagnostics. Co-Diagnostics' average media sentiment score of 0.29 beat GlucoTrack's score of 0.00 indicating that Co-Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Co-Diagnostics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GlucoTrack	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Co-Diagnostics has a beta of 2.88, meaning that its stock price is 188% more volatile than the broader market. Comparatively, GlucoTrack has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market.

Summary

Co-Diagnostics beats GlucoTrack on 10 of the 15 factors compared between the two stocks.

How does GlucoTrack compare to Quoin Pharmaceuticals?

GlucoTrack (NASDAQ:GCTK) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

Quoin Pharmaceuticals is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlucoTrack	N/A	N/A	-$19.39M	-$18.04	N/A
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A

In the previous week, GlucoTrack had 3 more articles in the media than Quoin Pharmaceuticals. MarketBeat recorded 4 mentions for GlucoTrack and 1 mentions for Quoin Pharmaceuticals. GlucoTrack's average media sentiment score of 0.00 equaled Quoin Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GlucoTrack	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quoin Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Quoin Pharmaceuticals' return on equity of -489.85% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GlucoTrack	N/A	-581.98%	-220.10%
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%

10.9% of GlucoTrack shares are owned by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. 8.4% of GlucoTrack shares are owned by company insiders. Comparatively, 11.2% of Quoin Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

GlucoTrack has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market.

Summary

Quoin Pharmaceuticals beats GlucoTrack on 6 of the 11 factors compared between the two stocks.

How does GlucoTrack compare to HeartSciences?

GlucoTrack (NASDAQ:GCTK) and HeartSciences (NASDAQ:HSCS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

In the previous week, HeartSciences had 9 more articles in the media than GlucoTrack. MarketBeat recorded 13 mentions for HeartSciences and 4 mentions for GlucoTrack. HeartSciences' average media sentiment score of 0.24 beat GlucoTrack's score of 0.00 indicating that HeartSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GlucoTrack	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
HeartSciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

10.9% of GlucoTrack shares are held by institutional investors. Comparatively, 17.2% of HeartSciences shares are held by institutional investors. 8.4% of GlucoTrack shares are held by company insiders. Comparatively, 4.9% of HeartSciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

HeartSciences has a consensus price target of $8.00, suggesting a potential upside of 273.83%. Given HeartSciences' stronger consensus rating and higher possible upside, analysts plainly believe HeartSciences is more favorable than GlucoTrack.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

GlucoTrack has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market. Comparatively, HeartSciences has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market.

HeartSciences' return on equity of -358.60% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GlucoTrack	N/A	-581.98%	-220.10%
HeartSciences	N/A	-358.60%	-144.82%

HeartSciences is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlucoTrack	N/A	N/A	-$19.39M	-$18.04	N/A
HeartSciences	N/A	N/A	-$9.14M	-$3.94	N/A

Summary

HeartSciences beats GlucoTrack on 11 of the 13 factors compared between the two stocks.

Get GlucoTrack News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GCTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GCTK vs. The Competition

Export

Metric	GlucoTrack	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.68M	$5.66B	$6.86B	$12.44B
Dividend Yield	N/A	1.78%	2.60%	10.03%
P/E Ratio	-0.02	23.65	280.74	24.99
Price / Sales	N/A	58.66	588.16	90.43
Price / Cash	N/A	32.53	28.64	34.82
Price / Book	0.15	6.51	11.02	6.21
Net Income	-$19.39M	$151.15M	$3.48B	$347.49M
7 Day Performance	38.30%	3.10%	0.81%	1.29%
1 Month Performance	29.66%	-1.09%	-4.15%	-3.59%
1 Year Performance	-93.11%	3.48%	61.47%	18.38%

GlucoTrack Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GCTK GlucoTrack	0.2136 of 5 stars	$0.41 -13.0%	N/A	-93.3%	$3.68M	N/A	N/A	5
ICCM IceCure Medical	2.6698 of 5 stars	$3.33 -0.9%	$62.70 +1,782.9%	-90.8%	$11.51M	$3.38M	N/A	60	Gap Down
NXL Nexalin Technology	0.3391 of 5 stars	$0.46 -4.1%	N/A	-63.1%	$10.59M	$300K	N/A	3	Gap Up
CODX Co-Diagnostics	1.7766 of 5 stars	$2.28 -3.4%	$67.50 +2,860.5%	-80.1%	$8.70M	$620K	N/A	100
QNRX Quoin Pharmaceuticals	0.8008 of 5 stars	$4.38 +2.8%	N/A	-33.2%	$8.56M	N/A	N/A	4	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GCTK) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GlucoTrack (GCTK) Competitors

GCTK vs. ICCM, NXL, CODX, QNRX, and HSCS

How does GlucoTrack compare to IceCure Medical?

Summary

How does GlucoTrack compare to Nexalin Technology?

Summary

How does GlucoTrack compare to Co-Diagnostics?

Summary

How does GlucoTrack compare to Quoin Pharmaceuticals?

Summary

How does GlucoTrack compare to HeartSciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GCTK vs. The Competition

GlucoTrack Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GlucoTrack (GCTK) Competitors

GCTK vs. ICCM, NXL, CODX, QNRX, and HSCS

How does GlucoTrack compare to IceCure Medical?

Do analysts rate ICCM or GCTK?

Is ICCM or GCTK more profitable?

Which has preferable valuation & earnings, ICCM or GCTK?

Does the media prefer ICCM or GCTK?

Which has more volatility and risk, ICCM or GCTK?

Do insiders & institutionals believe in ICCM or GCTK?

Summary

How does GlucoTrack compare to Nexalin Technology?

Do analysts recommend NXL or GCTK?

Which has better earnings & valuation, NXL or GCTK?

Is NXL or GCTK more profitable?

Which has more volatility and risk, NXL or GCTK?

Do institutionals and insiders hold more shares of NXL or GCTK?

Does the media prefer NXL or GCTK?

Summary

How does GlucoTrack compare to Co-Diagnostics?

Do insiders and institutionals hold more shares of CODX or GCTK?

Is CODX or GCTK more profitable?

Do analysts rate CODX or GCTK?

Which has preferable valuation & earnings, CODX or GCTK?

Does the media prefer CODX or GCTK?

Which has more risk and volatility, CODX or GCTK?

Summary

How does GlucoTrack compare to Quoin Pharmaceuticals?

Which has higher valuation and earnings, GCTK or QNRX?

Does the media favor GCTK or QNRX?

Do analysts rate GCTK or QNRX?

Is GCTK or QNRX more profitable?

Do institutionals & insiders believe in GCTK or QNRX?

Which has more volatility and risk, GCTK or QNRX?

Summary

How does GlucoTrack compare to HeartSciences?

Does the media refer more to GCTK or HSCS?

Do institutionals and insiders have more ownership in GCTK or HSCS?

Do analysts rate GCTK or HSCS?

Which has more volatility & risk, GCTK or HSCS?

Is GCTK or HSCS more profitable?

Which has stronger valuation and earnings, GCTK or HSCS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GCTK vs. The Competition

GlucoTrack Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools